北京大学学报(医学版) ›› 2022, Vol. 54 ›› Issue (6): 1074-1078. doi: 10.19723/j.issn.1671-167X.2022.06.003

• 论著 • 上一篇    下一篇

CCL28-CCR10通路在类风湿关节炎单核细胞迁移中的作用

程昉1,*(),杨邵英2,房星星3,王璇3,赵福涛1,*()   

  1. 1. 上海交通大学医学院附属第九人民医院风湿免疫科,上海 201999
    2. 上海交通大学医学院附属仁济医院风湿科,上海 200001
    3. 同济大学附属同济医院风湿免疫科,上海 200065
  • 收稿日期:2022-07-13 出版日期:2022-12-18 发布日期:2022-12-19
  • 通讯作者: 程昉,赵福涛 E-mail:chengfangsmmu@126.com;ftzhao@moisten.org
  • 基金资助:
    国家自然科学基金(81302562)

Role of the CCL28-CCR10 pathway in monocyte migration in rheumatoid arthritis

Fang CHENG1,*(),Shao-ying YANG2,Xing-xing FANG3,Xuan WANG3,Fu-tao ZHAO1,*()   

  1. 1. Department of Rheumatology and Immunology, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 201999, China
    2. Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200001, China
    3. Department of Rheumatology and Immunology, Tongji Hospital, Tongji University, Shanghai 200065, China
  • Received:2022-07-13 Online:2022-12-18 Published:2022-12-19
  • Contact: Fang CHENG,Fu-tao ZHAO E-mail:chengfangsmmu@126.com;ftzhao@moisten.org
  • Supported by:
    the National Natural Science Foundation of China(81302562)

RICH HTML

  

摘要:

目的: 观察类风湿关节炎(rheumatoid arthritis,RA)患者关节中单核/巨噬细胞趋化因子受体CCR10的表达,探讨趋化因子CCL28与其受体CCR10在RA单核细胞迁移中的作用及机制。方法: 采用免疫组织化学法分析8例RA患者、4例骨关节炎(osteoarthritis,OA)患者和4例正常对照者滑膜组织中CCR10的表达并进行细胞染色评分(0~5分),流式细胞术检测26例RA患者和20例健康对照者外周血、15例RA患者滑液CD14+单核细胞中CCR10阳性细胞比例,Transwell迁移实验检测CCL28对RA和健康对照单核细胞的趋化性,Western blotting检测CCL28干预RA单核细胞的细胞外信号调节激酶(extracellular signal-regulated kinase,ERK)、蛋白激酶B(protein kinase B,Akt)通路磷酸化。结果: CCR10表达在RA滑膜衬里层细胞及衬里下层的巨噬细胞、血管内皮细胞、淋巴细胞;RA滑膜衬里层细胞和衬里下层巨噬细胞的CCR10表达明显高于OA和正常对照的滑膜(P均 < 0.01)。RA患者外周血CD14+单核细胞表达CCR10明显高于健康对照者[(15.6±3.0)% vs. (7.7±3.8)%, P < 0.01];RA患者滑液单核细胞CCR10的表达为(32.0±15.0)%,明显高于RA外周血(P < 0.01)。体外实验中,10~100 μg/L的CCL28能有效诱导RA和健康对照外周血CD14+单核细胞迁移(P均 < 0.01);抗CCR10单抗能明显抑制CCL28对RA单核细胞的趋化(P < 0.01)。CCL28干预RA单核细胞明显增加ERK和Akt的磷酸化(P均 < 0.05);ERK抑制剂(U0126)、磷脂酰肌醇3-激酶(phosphatidylinositol 3-kinase,PI3K)抑制剂(LY294002)可明显降低CCL28诱导的RA单核细胞迁移(P均 < 0.01)。结论: RA患者外周血、滑液及滑膜单核/巨噬细胞CCR10表达增高,CCL28与CCR10结合并通过激活ERK、PI3K/Akt信号通路促使RA单核细胞迁移;CCL28-CCR10通路可能参与招募单核细胞进入RA关节,从而促进滑膜炎症和骨破坏。

关键词: 类风湿关节炎, 单核细胞, 趋化因子CCL28, 趋化因子受体CCR10

Abstract:

Objective: To examine the expression of chemokine receptor CCR10 on monocytes/macrophages in the joints of patients with rheumatoid arthritis (RA), and to investigate the role of chemokine CCL28 and its receptor CCR10 in the migration of RA monocytes and its mechanism. Methods: The expression of CCR10 in synovial tissues from 8 RA patients, 4 osteoarthritis (OA) patients, and 4 normal controls was analyzed by immunohistochemistry, and cell staining was scored on a 0-5 scales. Flow cytometry was used to measure the percentage of CCR10 positive cells in CD14+ monocytes from peripheral blood of 26 RA patients and 20 healthy controls, as well as from synovial fluid of 15 RA patients. The chemotactic migration of monocytes from RA patients and healthy controls in response to CCL28 was evaluated using an in vitro Transwell system. Western blotting was conducted to assess phosphorylation of the extracellular signal-regulated kinase (ERK) and protein kinase B (Akt) pathways in RA monocytes upon CCL28 treatment. Results: CCR10 was predominantly expressed in RA synovial lining cells and sublining macrophages, endothelial cells, and lymphocytes. CCR10 expression was significantly increased on lining cells and sublining macrophages in RA synovial tissue compared with OA and normal synovial tissue (both P < 0.01). The patients with RA had markedly elevated expression of CCR10 on peripheral blood CD14+ monocytes compared with the healthy controls [(15.6±3.0)% vs. (7.7±3.8)%, P < 0.01]. CCR10 expression on synovial fluid monocytes from the RA patients was (32.0±15.0)%, which was significantly higher than that on RA peripheral blood monocytes (P < 0.01). In vitro, CCL28 caused significant migration of CD14+ monocytes from peripheral blood of the RA patients and the healthy controls at concentrations ranging from 10-100 μg/L (all P < 0.01). The presence of neutralizing antibody to CCR10 greatly suppressed CCL28-driven chemotaxis of RA monocytes (P < 0.01). Stimulation of RA monocytes with CCL28 induced a remarkable increase in phosphorylation of ERK and Akt (both P < 0.05). ERK inhibitor (U0126) and phosphatidylinositol 3-kinase (PI3K) inhibitor (LY294002) strongly reduced the migration of RA monocytes in response to CCL28 (both P < 0.01). Conclusion: RA patients had increased CCR10 expression on peripheral blood, synovial fluid, and synovial tissue monocytes/macrophages. CCL28 ligation to CCR10 promoted RA monocyte migration through activation of the ERK and PI3K/Akt signaling pathways. The CCL28-CCR10 pathway could participate in monocyte recruitment into RA joints, thereby contributing to synovial inflammation and bone destruction.

Key words: Rheumatoid arthritis, Monocytes, Chemokine CCL28, Chemokine receptor CCR10

中图分类号: 

  • R593.22

图1

滑膜组织中CCR10的表达(免疫组织化学染色)"

图2

外周血和滑液单核细胞CCR10表达水平比较"

图3

CCL28对单核细胞的趋化作用"

图4

CCL28干预后单核细胞ERK、Akt信号通路磷酸化水平"

图5

抑制CCR10、ERK、PI3K/Akt对CCL28趋化单核细胞的影响"

1 Sparks JA . Rheumatoid arthritis[J]. Ann Intern Med, 2019, 170 (1): ITC1- ITC16.
doi: 10.7326/AITC201901010
2 Jang S , Kwon EJ , Lee JJ . Rheumatoid arthritis: Pathogenic roles of diverse immune cells[J]. Int J Mol Sci, 2022, 23 (2): 905.
doi: 10.3390/ijms23020905
3 Szekanecz Z , Koch AE . Successes and failures of chemokine-pathway targeting in rheumatoid arthritis[J]. Nat Rev Rheumatol, 2016, 12 (1): 5- 13.
doi: 10.1038/nrrheum.2015.157
4 Pan J , Kunkel EJ , Gosslar U , et al. A novel chemokine ligand for CCR10 and CCR3 expressed by epithelial cells in mucosal tissues[J]. J Immunol, 2000, 165 (6): 2943- 2949.
doi: 10.4049/jimmunol.165.6.2943
5 Wang W , Soto H , Oldham ER , et al. Identification of a novel chemokine (CCL28), which binds CCR10 (GPR2)[J]. J Biol Chem, 2000, 275 (29): 22313- 22323.
doi: 10.1074/jbc.M001461200
6 Mohan T , Deng L , Wang BZ . CCL28 chemokine: An anchoring point bridging innate and adaptive immunity[J]. Int Immuno-pharmacol, 2017, 51, 165- 170.
doi: 10.1016/j.intimp.2017.08.012
7 Chen Z , Kim SJ , Essani AB , et al. Characterising the expression and function of CCL28 and its corresponding receptor, CCR10, in RA pathogenesis[J]. Ann Rheum Dis, 2015, 74 (10): 1898- 1906.
doi: 10.1136/annrheumdis-2013-204530
8 Miyazaki Y , Nakayamada S , Kubo S , et al. Th22 cells promote osteoclast differentiation via production of IL-22 in rheumatoid arthritis[J]. Front Immunol, 2018, 9, 2901.
doi: 10.3389/fimmu.2018.02901
9 Aletaha D , Neogi T , Silman AJ , et al. 2010 rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative[J]. Arthritis Rheum, 2010, 62 (9): 2569- 2581.
doi: 10.1002/art.27584
10 Rana AK , Li Y , Dang Q , et al. Monocytes in rheumatoid arthritis: Circulating precursors of macrophages and osteoclasts and, their heterogeneity and plasticity role in RA pathogenesis[J]. Int Immunopharmacol, 2018, 65, 348- 359.
doi: 10.1016/j.intimp.2018.10.016
11 Park J , Zhang X , Lee SK , et al. CCL28-induced RARβ expression inhibits oral squamous cell carcinoma bone invasion[J]. J Clin Invest, 2019, 129 (12): 5381- 5399.
doi: 10.1172/JCI125336
12 Facciabene A , Peng X , Hagemann IS , et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells[J]. Nature, 2011, 475 (7355): 226- 230.
doi: 10.1038/nature10169
13 Wu Q , Chen JX , Chen Y , et al. The chemokine receptor CCR10 promotes inflammation-driven hepatocarcinogenesis via PI3K/Akt pathway activation[J]. Cell Death Dis, 2018, 9 (2): 232.
doi: 10.1038/s41419-018-0267-9
[1] 魏慧, 张警丰, 姚中强, 赵金霞. 类风湿关节炎合并慢性病贫血患者的临床特征及相关因素[J]. 北京大学学报(医学版), 2026, 58(2): 307-312.
[2] 吴滔, 林建子, 朱亚锋, 马剑达, 贾霈雯, 杨莉娟, 潘婕, 邹耀威, 杨迎, 卢烨, 戴冽. 血清蛋白质谱筛选及验证类风湿关节炎患者肌肉量减少的生物标志物[J]. 北京大学学报(医学版), 2025, 57(6): 1024-1031.
[3] 丁艳, 王丽芳, 李超然, 卢哲敏, 石连杰. 利妥昔单抗成功治疗类风湿关节炎合并IgG4相关性疾病1例[J]. 北京大学学报(医学版), 2025, 57(6): 1203-1207.
[4] 杨菊, 徐婧, 戴菊华, 石连杰. Lumican蛋白在类风湿关节炎患者血清中的表达及其与疾病和免疫活动的相关性[J]. 北京大学学报(医学版), 2025, 57(5): 911-918.
[5] 冯亮华, 洪丽荣, 陈雨佳, 蔡学明. 泛素特异性蛋白酶35对类风湿关节炎成纤维样滑膜细胞铁死亡的作用及机制[J]. 北京大学学报(医学版), 2025, 57(5): 919-925.
[6] 贾霈雯, 杨迎, 邹耀威, 欧阳志明, 林建子, 马剑达, 杨葵敏, 戴冽. 类风湿关节炎患者低肌肉量综合征的临床特征及其对躯体功能的影响[J]. 北京大学学报(医学版), 2024, 56(6): 1009-1016.
[7] 马豆豆, 卢哲敏, 郭倩, 朱莎, 古今, 丁艳, 石连杰. 小剂量利妥昔单抗成功治疗类风湿关节炎合并重症肌无力1例[J]. 北京大学学报(医学版), 2024, 56(6): 1110-1114.
[8] 闫蕊, 柯丹, 张妍, 李丽, 苏焕然, 陈伟, 孙明霞, 刘晓敏, 罗靓. 血清趋化因子CXCL-10和涎液化糖链抗原6水平在类风湿关节炎合并肺间质病变患者中的诊断和病情评估价值[J]. 北京大学学报(医学版), 2024, 56(6): 956-962.
[9] 赵亮, 史成龙, 马柯, 赵静, 王潇, 邢晓燕, 莫万星, 练益瑞, 高超, 李玉慧. 抗合成酶综合征重叠类风湿关节炎患者的免疫学特征[J]. 北京大学学报(医学版), 2024, 56(6): 972-979.
[10] 韩艺钧, 陈小莉, 李常虹, 赵金霞. 甲氨蝶呤在类风湿关节炎患者中的应用现状[J]. 北京大学学报(医学版), 2024, 56(6): 994-1000.
[11] 刘东武, 陈杰, 高明利, 于静. 类风湿关节炎伴发淋巴结Castleman样病理改变1例[J]. 北京大学学报(医学版), 2024, 56(5): 928-931.
[12] 黄会娜,赵静,赵祥格,白自然,李霞,王冠. 乳酸对类风湿关节炎患者外周血CD4+T细胞亚群的调控作用[J]. 北京大学学报(医学版), 2024, 56(3): 519-525.
[13] 汤晓菲,李永红,丁秋玲,孙卓,张阳,王育梅,田美伊,刘坚. 类风湿关节炎患者下肢深静脉血栓发病率及危险因素[J]. 北京大学学报(医学版), 2024, 56(2): 279-283.
[14] 邹雪,白小娟,张丽卿. 艾拉莫德联合托法替布治疗难治性中重度类风湿关节炎的疗效[J]. 北京大学学报(医学版), 2023, 55(6): 1013-1021.
[15] 吴琦,蔡月明,何娟,黄文蒂,王庆文. 血脂异常与类风湿关节炎肺间质病变的相关性分析[J]. 北京大学学报(医学版), 2023, 55(6): 982-992.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!